← 返回

Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve.

Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve.

期刊: JACC. Cardiovascular interventions 日期: 2026-08-10 PMID: 42575581 DOI: 10.1016/j.jcin.2026.05.028 浏览: 10
作者: Tanigaki T, Mizukami T, Arai T, Hagiya K, Kikuta Y, Yoshida T, Yamamoto H, Takahara M, Isodono K, Kawase Y
T, T., T, M., T, A., K, H., Y, K., T, Y., H, Y., M, T., K, I., & Y, K. (2026). Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve.. JACC. Cardiovascular interventions. https://doi.org/10.1016/j.jcin.2026.05.028
T T, T M, T A, K H, Y K, T Y, et al. Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve.. JACC. Cardiovascular interventions. 2026; doi: 10.1016/j.jcin.2026.05.028
T T, T M, T A, et al. Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve.[J]. JACC. Cardiovascular interventions. 2026. DOI: 10.1016/j.jcin.2026.05.028.
@article{t2026,
  author = {Tanigaki T and Mizukami T and Arai T and Hagiya K and Kikuta Y and Yoshida T and Yamamoto H and Takahara M and Isodono K and Kawase Y},
  title = {Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve.},
  journal = {JACC. Cardiovascular interventions},
  year = {2026},
  doi = {10.1016/j.jcin.2026.05.028},
  note = {PMID: 42575581},
}
TY  - JOUR
AU  - Tanigaki T
AU  - Mizukami T
AU  - Arai T
AU  - Hagiya K
AU  - Kikuta Y
AU  - Yoshida T
AU  - Yamamoto H
AU  - Takahara M
AU  - Isodono K
AU  - Kawase Y
TI  - Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve.
T2  - JACC. Cardiovascular interventions
PY  - 2026
DO  - 10.1016/j.jcin.2026.05.028
AN  - PMID:42575581
ER  - 

摘要

BACKGROUND: Pressure wire-based fractional flow reserve (FFR) is the reference standard for physiologic lesion assessment but remains underutilized owing to the need for hyperemia, procedural complexity, and wire-related risks. Angiography-derived FFR provides a wire- and hyperemia-free assessment derived from routine angiography; however, its clinical impact in guiding treatment remains uncertain. OBJECTIVES: This study aimed to determine whether angiography-derived FFR is noninferior to pressure wire-based FFR in guiding revascularization decisions among patients with stable coronary artery disease. METHODS: PROVISION (Prospective randomized trial of clinical outcomes of angiography-based fractional flow reserve guidance versus wire-based fractional flow reserve guidance) was a prospective, multicenter, randomized study. Participants were randomized 1:1 to angiography-derived FFR-guided or pressure wire-based FFR-guided revascularization. The primary endpoint was the noninferiority of angiography-derived FFR in terms of revascularization rate, defined as the proportion of patients undergoing percutaneous coronary intervention or coronary artery bypass grafting based on physiologic assessment. Secondary endpoints included the 1-year incidence of major adverse cardiac events (cardiac death, any myocardial infarction, or ischemia-driven target vessel revascularization). RESULTS: Overall, 401 patients (483 vessels) were enrolled at 13 Japanese centers. Revascularization was performed in 41.4% of patients in the angiography-derived FFR group and 37.9% in the pressure wire-based FFR group (absolute difference: 3.5%; 95% CI: -6.0 to 13.1; P for noninferiority = 0.049). At 1 year, major adverse cardiovascular events occurred in 8.4% and 10.1% of patients, respectively (HR: 0.84; 95% CI: 0.44-1.60; P = 0.591). CONCLUSIONS: Angiography-derived FFR-guided revascularization was noninferior to pressure wire-based FFR-guided strategy for determining revascularization in patients with stable coronary artery disease. This finding suggests that angiography-derived FFR may serve as a practical, wire-free alternative for physiologic guidance of coronary revascularization, warranting confirmation in larger outcome-driven trials. (PROVISION; UMIN000049230).

AI 智能解读

相关文献

返回分类: 冠心病 查看原文 (DOI)
已选择 0 篇文献